{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3602, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "transition", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/23", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-23", "loopMatches": [], "arcBeatMatches": [ { "to": 27, "from": 4, "beatId": "e890a8f4-ce5b-494a-9258-fdd0f87cc84b", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Interest", "beatSlug": "aida-interest", "evidence": "The deck presents the problem, solution, competitive analysis, and traction", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a red dashed box to highlight the primary efficacy metrics (response rates).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/24", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-24", "loopMatches": [], "arcBeatMatches": [ { "to": 27, "from": 4, "beatId": "e890a8f4-ce5b-494a-9258-fdd0f87cc84b", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Interest", "beatSlug": "aida-interest", "evidence": "The deck presents the problem, solution, competitive analysis, and traction", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "traction", "function": "show_traction", "notes": "The chart uses a grouped bar structure to compare efficacy across patient segments (No BCMA, Yes BCMA, Overall).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/25", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-25", "loopMatches": [], "arcBeatMatches": [ { "to": 27, "from": 4, "beatId": "e890a8f4-ce5b-494a-9258-fdd0f87cc84b", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Interest", "beatSlug": "aida-interest", "evidence": "The deck presents the problem, solution, competitive analysis, and traction", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a comparison table framework to highlight competitive advantage in clinical metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/26", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-26", "loopMatches": [], "arcBeatMatches": [ { "to": 27, "from": 4, "beatId": "e890a8f4-ce5b-494a-9258-fdd0f87cc84b", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Interest", "beatSlug": "aida-interest", "evidence": "The deck presents the problem, solution, competitive analysis, and traction", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "traction", "function": "show_traction", "notes": "The slide uses a two-column layout to compare clinical data for two different indications, supported by competitor market data.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/27", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-27", "loopMatches": [], "arcBeatMatches": [ { "to": 27, "from": 4, "beatId": "e890a8f4-ce5b-494a-9258-fdd0f87cc84b", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Interest", "beatSlug": "aida-interest", "evidence": "The deck presents the problem, solution, competitive analysis, and traction", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "traction", "function": "show_traction", "notes": "The chart illustrates deepening responses over time in a clinical trial setting.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/28", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-28", "loopMatches": [], "arcBeatMatches": [ { "to": 45, "from": 28, "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Desire", "beatSlug": "aida-desire", "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "appendix_data", "function": "analyze_data", "notes": "The table displays clinical trial data for NXC-201, specifically focusing on Cytokine Release Syndrome (CRS) and Immune cell associated Neurotoxicity (ICANS).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/29", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-29", "loopMatches": [], "arcBeatMatches": [ { "to": 45, "from": 28, "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Desire", "beatSlug": "aida-desire", "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The slide highlights specific safety metrics (CRS and ICANS) for two dosage groups (100x10^6 and 300x10^6 cells).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/30", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-30", "loopMatches": [], "arcBeatMatches": [ { "to": 45, "from": 28, "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Desire", "beatSlug": "aida-desire", "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "roadmap", "function": "plan_implementation", "notes": "Includes FDA approval precedents in the footer.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/31", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-31", "loopMatches": [], "arcBeatMatches": [ { "to": 45, "from": 28, "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Desire", "beatSlug": "aida-desire", "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "appendix_methodology", "function": "plan_implementation", "notes": "The diagram illustrates a classic dose-escalation study design.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/32", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-32", "loopMatches": [], "arcBeatMatches": [ { "to": 45, "from": 28, "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Desire", "beatSlug": "aida-desire", "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "testimonial", "function": "illustrate_case", "notes": "The slide uses a mix of expert quotes and a comparative table of clinical trials to validate the outpatient therapy thesis.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/33", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-33", "loopMatches": [], "arcBeatMatches": [ { "to": 45, "from": 28, "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Desire", "beatSlug": "aida-desire", "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "section_divider", "function": "transition", "notes": "The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/34", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-34", "loopMatches": [], "arcBeatMatches": [ { "to": 45, "from": 28, "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Desire", "beatSlug": "aida-desire", "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "solution", "function": "present_solution", "notes": "Includes scientific diagrams of molecular pathways and efficacy charts.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/35", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-35", "loopMatches": [], "arcBeatMatches": [ { "to": 45, "from": 28, "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Desire", "beatSlug": "aida-desire", "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "traction", "function": "show_traction", "notes": "Slide contains three distinct data visualizations comparing IMX-110 against standard of care or historical benchmarks.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/36", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-36", "loopMatches": [], "arcBeatMatches": [ { "to": 45, "from": 28, "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Desire", "beatSlug": "aida-desire", "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "traction", "function": "show_traction", "notes": "Includes a process flow diagram illustrating the mechanism of action of iMX-110 in turning cold tumors hot.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/37", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-37", "loopMatches": [], "arcBeatMatches": [ { "to": 45, "from": 28, "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Desire", "beatSlug": "aida-desire", "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 38, "slideType": "traction", "function": "show_traction", "notes": "Includes survival curves, median survival comparison, and bioluminescence imaging of tumor activity.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/38", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-38", "loopMatches": [], "arcBeatMatches": [ { "to": 45, "from": 28, "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Desire", "beatSlug": "aida-desire", "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 39, "slideType": "transition", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/39", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-39", "loopMatches": [], "arcBeatMatches": [ { "to": 45, "from": 28, "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Desire", "beatSlug": "aida-desire", "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 40, "slideType": "traction", "function": "show_traction", "notes": "Includes waterfall chart for best percentage change and line charts for longitudinal tumor size tracking against PD/PR thresholds.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/40", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-40", "loopMatches": [], "arcBeatMatches": [ { "to": 45, "from": 28, "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Desire", "beatSlug": "aida-desire", "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 41, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a scatter plot to map clinical trial outcomes (mPFS vs. prior lines of therapy) and a table to detail standard-of-care performance across lines of therapy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/41", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-41", "loopMatches": [], "arcBeatMatches": [ { "to": 45, "from": 28, "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Desire", "beatSlug": "aida-desire", "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 42, "slideType": "traction", "function": "show_traction", "notes": "The slide uses a combination of a conceptual chart and a data table to highlight efficacy and safety in a late-stage patient population.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/42", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-42", "loopMatches": [], "arcBeatMatches": [ { "to": 45, "from": 28, "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Desire", "beatSlug": "aida-desire", "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 43, "slideType": "roadmap", "function": "plan_implementation", "notes": "Includes logos for BeiGene and Novartis at the bottom.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/43", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-43", "loopMatches": [], "arcBeatMatches": [ { "to": 45, "from": 28, "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Desire", "beatSlug": "aida-desire", "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 44, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/44", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-44", "loopMatches": [], "arcBeatMatches": [ { "to": 45, "from": 28, "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Desire", "beatSlug": "aida-desire", "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 45, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a process-flow style layout to connect platform capabilities to specific therapeutic assets.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/45", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-45", "loopMatches": [], "arcBeatMatches": [ { "to": 45, "from": 28, "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Desire", "beatSlug": "aida-desire", "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 46, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a process-like structure to map the platform pillars to specific product outputs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/46", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-46", "loopMatches": [], "arcBeatMatches": [ { "to": 58, "from": 46, "beatId": "4e07e972-cafc-486f-912e-2418cf212a13", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Action", "beatSlug": "aida-action", "evidence": "The deck concludes with a call to action and future plans", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 47, "slideType": "solution", "function": "present_solution", "notes": "Includes technical diagrams of the drug molecule, comparative histology, and survival curves.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/47", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-47", "loopMatches": [], "arcBeatMatches": [ { "to": 58, "from": 46, "beatId": "4e07e972-cafc-486f-912e-2418cf212a13", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Action", "beatSlug": "aida-action", "evidence": "The deck concludes with a call to action and future plans", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 48, "slideType": "traction", "function": "show_traction", "notes": "Includes two sets of charts: tumor volume line graphs and survival curves. References specific dosing schedules and study parameters.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/48", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-48", "loopMatches": [], "arcBeatMatches": [ { "to": 58, "from": 46, "beatId": "4e07e972-cafc-486f-912e-2418cf212a13", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Action", "beatSlug": "aida-action", "evidence": "The deck concludes with a call to action and future plans", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 49, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a combination of mechanism-of-action diagrams and clinical/preclinical data charts to validate the therapeutic approach.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/49", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-49", "loopMatches": [], "arcBeatMatches": [ { "to": 58, "from": 46, "beatId": "4e07e972-cafc-486f-912e-2418cf212a13", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Action", "beatSlug": "aida-action", "evidence": "The deck concludes with a call to action and future plans", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 50, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/50", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-50", "loopMatches": [], "arcBeatMatches": [ { "to": 58, "from": 46, "beatId": "4e07e972-cafc-486f-912e-2418cf212a13", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Action", "beatSlug": "aida-action", "evidence": "The deck concludes with a call to action and future plans", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 51, "slideType": "team_bio", "function": "other", "notes": "The slide is divided into two sections: ImmixBio Clinical Advisory Board and Select Nexcella Scientific Advisory Board Members.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/51", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-51", "loopMatches": [], "arcBeatMatches": [ { "to": 58, "from": 46, "beatId": "4e07e972-cafc-486f-912e-2418cf212a13", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Action", "beatSlug": "aida-action", "evidence": "The deck concludes with a call to action and future plans", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 52, "slideType": "team_bio", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/52", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-52", "loopMatches": [], "arcBeatMatches": [ { "to": 58, "from": 46, "beatId": "4e07e972-cafc-486f-912e-2418cf212a13", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Action", "beatSlug": "aida-action", "evidence": "The deck concludes with a call to action and future plans", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 53, "slideType": "team_bio", "function": "other", "notes": "The slide is organized into two rows, one for each board, featuring headshots, names, titles, and associated company logos.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/53", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-53", "loopMatches": [], "arcBeatMatches": [ { "to": 58, "from": 46, "beatId": "4e07e972-cafc-486f-912e-2418cf212a13", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Action", "beatSlug": "aida-action", "evidence": "The deck concludes with a call to action and future plans", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 54, "slideType": "executive_summary", "function": "summarize", "notes": "The slide uses a numbered list format to present key value propositions.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/54", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-54", "loopMatches": [], "arcBeatMatches": [ { "to": 58, "from": 46, "beatId": "4e07e972-cafc-486f-912e-2418cf212a13", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Action", "beatSlug": "aida-action", "evidence": "The deck concludes with a call to action and future plans", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 55, "slideType": "appendix", "function": "appendix", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/55", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-55", "loopMatches": [], "arcBeatMatches": [ { "to": 58, "from": 46, "beatId": "4e07e972-cafc-486f-912e-2418cf212a13", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Action", "beatSlug": "aida-action", "evidence": "The deck concludes with a call to action and future plans", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 56, "slideType": "comparison_table", "function": "compare_peers", "notes": "Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/56", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-56", "loopMatches": [], "arcBeatMatches": [ { "to": 58, "from": 46, "beatId": "4e07e972-cafc-486f-912e-2418cf212a13", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Action", "beatSlug": "aida-action", "evidence": "The deck concludes with a call to action and future plans", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 57, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a bar chart to compare two groups of oncology drugs, highlighting a significant revenue disparity.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/57", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-57", "loopMatches": [], "arcBeatMatches": [ { "to": 58, "from": 46, "beatId": "4e07e972-cafc-486f-912e-2418cf212a13", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Action", "beatSlug": "aida-action", "evidence": "The deck concludes with a call to action and future plans", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d6ea-7495-b63c-e64074d45b72", "docSlug": "3f99bbe59467be363a98d21e99cb078a", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 58, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a bar chart comparison to benchmark existing market leaders against placebo outcomes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/58", "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72", "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-58", "loopMatches": [], "arcBeatMatches": [ { "to": 58, "from": 46, "beatId": "4e07e972-cafc-486f-912e-2418cf212a13", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Action", "beatSlug": "aida-action", "evidence": "The deck concludes with a call to action and future plans", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/7V0HuiTi0k4uTwSieo2pfYojYGoUdIqAqw5SqyizqJc/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zZGQ3OWJiMjA5NmNlZWFmMWFjODNiMDMyZDAyZmE3Ny9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/1", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-1", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "06b240bd-3d61-4786-acf2-c0f962191eb9", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Humble Origins", "beatSlug": "rags-to-riches-humble-origins", "evidence": "Kering's history and transformation", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": "https://imgproxy.kitesheet.com/b9AK9P-whv6OsxT0clNAgzl0MvjHJoONgxjxgTcIRtE/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zZGQ3OWJiMjA5NmNlZWFmMWFjODNiMDMyZDAyZmE3Ny9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/kD8QV0Li3lIXYZG9RKpNsu-dhT3AgFGzpZ4vrkLkV8Y/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zZGQ3OWJiMjA5NmNlZWFmMWFjODNiMDMyZDAyZmE3Ny9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/FMoCEu2NBc00KnIUa9y02OkU1jZpGe5y9cb5CuVxLIE/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zZGQ3OWJiMjA5NmNlZWFmMWFjODNiMDMyZDAyZmE3Ny9wMDAxLnBuZw" }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/2", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-2", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "06b240bd-3d61-4786-acf2-c0f962191eb9", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Humble Origins", "beatSlug": "rags-to-riches-humble-origins", "evidence": "Kering's history and transformation", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/3", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-3", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "06b240bd-3d61-4786-acf2-c0f962191eb9", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Humble Origins", "beatSlug": "rags-to-riches-humble-origins", "evidence": "Kering's history and transformation", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "kpi_overview", "function": "summarize", "notes": "The slide uses a grid layout to present six distinct performance categories.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/4", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-4", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "06b240bd-3d61-4786-acf2-c0f962191eb9", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Humble Origins", "beatSlug": "rags-to-riches-humble-origins", "evidence": "Kering's history and transformation", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "roadmap", "function": "present_solution", "notes": "The slide uses a process-oriented layout to show four strategic pillars leading to a unified outcome.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/5", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-5", "loopMatches": [], "arcBeatMatches": [ { "to": 8, "from": 5, "beatId": "c0627c35-79ed-4780-b9d2-8371e3b9b4c9", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Early Struggles", "beatSlug": "rags-to-riches-early-struggles", "evidence": "Challenges faced during transformation", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "key_takeaways", "function": "summarize", "notes": "The slide uses a timeline to show the divestment of non-luxury assets and acquisition of luxury brands, alongside donut charts to illustrate the shift in revenue composition.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/6", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-6", "loopMatches": [], "arcBeatMatches": [ { "to": 8, "from": 5, "beatId": "c0627c35-79ed-4780-b9d2-8371e3b9b4c9", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Early Struggles", "beatSlug": "rags-to-riches-early-struggles", "evidence": "Challenges faced during transformation", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The slide uses a mix of brand logos and a bar chart to illustrate portfolio composition and financial scale.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/7", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-7", "loopMatches": [], "arcBeatMatches": [ { "to": 8, "from": 5, "beatId": "c0627c35-79ed-4780-b9d2-8371e3b9b4c9", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Early Struggles", "beatSlug": "rags-to-riches-early-struggles", "evidence": "Challenges faced during transformation", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "before_after", "function": "present_solution", "notes": "Uses a before-after framework to illustrate strategic evolution.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/8", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-8", "loopMatches": [ { "to": 9, "from": 8, "name": "Before After", "slug": "21-before-after", "bestFor": "Product demos, process improvements, ROI justification", "matchId": "a30592c6-d8e8-4868-9a9b-1351b582c8dd", "evidence": "Comparison of Kering's past and present", "position": 0, "objective": "Showcasing Kering's transformation", "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta", "confidence": 0.8, "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison" } ], "arcBeatMatches": [ { "to": 8, "from": 5, "beatId": "c0627c35-79ed-4780-b9d2-8371e3b9b4c9", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Early Struggles", "beatSlug": "rags-to-riches-early-struggles", "evidence": "Challenges faced during transformation", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "key_takeaways", "function": "summarize", "notes": "The slide uses a split-screen layout comparing Kering Eyewear (historical growth chart) and Kering Beauté (timeline of recent developments).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/9", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-9", "loopMatches": [ { "to": 9, "from": 8, "name": "Before After", "slug": "21-before-after", "bestFor": "Product demos, process improvements, ROI justification", "matchId": "a30592c6-d8e8-4868-9a9b-1351b582c8dd", "evidence": "Comparison of Kering's past and present", "position": 0, "objective": "Showcasing Kering's transformation", "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta", "confidence": 0.8, "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison" } ], "arcBeatMatches": [ { "to": 16, "from": 9, "beatId": "bc8fc177-7a8e-40b3-b1bc-5dc6c7db515c", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Rising Success", "beatSlug": "rags-to-riches-rising-success", "evidence": "Kering's growth and achievements", "position": 2, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "key_messages", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/10", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-10", "loopMatches": [], "arcBeatMatches": [ { "to": 16, "from": 9, "beatId": "bc8fc177-7a8e-40b3-b1bc-5dc6c7db515c", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Rising Success", "beatSlug": "rags-to-riches-rising-success", "evidence": "Kering's growth and achievements", "position": 2, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "team_bio", "function": "introduce_nominees", "notes": "Includes a quote from the CEO and a visual representation of the top leadership hierarchy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/11", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-11", "loopMatches": [], "arcBeatMatches": [ { "to": 16, "from": 9, "beatId": "bc8fc177-7a8e-40b3-b1bc-5dc6c7db515c", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Rising Success", "beatSlug": "rags-to-riches-rising-success", "evidence": "Kering's growth and achievements", "position": 2, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/12", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-12", "loopMatches": [], "arcBeatMatches": [ { "to": 16, "from": 9, "beatId": "bc8fc177-7a8e-40b3-b1bc-5dc6c7db515c", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Rising Success", "beatSlug": "rags-to-riches-rising-success", "evidence": "Kering's growth and achievements", "position": 2, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "kpi_overview", "function": "analyze_data", "notes": "Waterfall chart shows H1 22 to H1 23 bridge with Comparable, Scope, and FX impacts. Donut chart includes a central map graphic.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/13", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-13", "loopMatches": [], "arcBeatMatches": [ { "to": 16, "from": 9, "beatId": "bc8fc177-7a8e-40b3-b1bc-5dc6c7db515c", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Rising Success", "beatSlug": "rags-to-riches-rising-success", "evidence": "Kering's growth and achievements", "position": 2, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "kpi_overview", "function": "analyze_data", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/14", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-14", "loopMatches": [], "arcBeatMatches": [ { "to": 16, "from": 9, "beatId": "bc8fc177-7a8e-40b3-b1bc-5dc6c7db515c", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Rising Success", "beatSlug": "rags-to-riches-rising-success", "evidence": "Kering's growth and achievements", "position": 2, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The slide uses a donut chart to show the 77%/23% split between Retail and Wholesale, with further regional and sub-channel breakdowns.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/15", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-15", "loopMatches": [], "arcBeatMatches": [ { "to": 16, "from": 9, "beatId": "bc8fc177-7a8e-40b3-b1bc-5dc6c7db515c", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Rising Success", "beatSlug": "rags-to-riches-rising-success", "evidence": "Kering's growth and achievements", "position": 2, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The slide highlights investment activities and financial health indicators.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/16", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-16", "loopMatches": [], "arcBeatMatches": [ { "to": 16, "from": 9, "beatId": "bc8fc177-7a8e-40b3-b1bc-5dc6c7db515c", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Rising Success", "beatSlug": "rags-to-riches-rising-success", "evidence": "Kering's growth and achievements", "position": 2, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/17", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-17", "loopMatches": [ { "to": 24, "from": 17, "name": "Maturity Curve", "slug": "36-maturity-curve", "bestFor": "Digital transformation, capability building, benchmarking", "matchId": "f2340bcf-90ff-467f-bfcf-04f4f4e81e7e", "evidence": "Kering's progress in the luxury market", "position": 1, "objective": "Highlighting Kering's growth and maturity", "structure": "Current Maturity Level -> The Gap to Next Level -> Required Capabilities -> The Roadmap", "confidence": 0.7, "description": "Show where you are on a progression and what it takes to reach the next level" } ], "arcBeatMatches": [ { "to": 24, "from": 17, "beatId": "7cb44931-e742-4b4f-91aa-50eb6555992e", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "The Breakthrough", "beatSlug": "rags-to-riches-the-breakthrough", "evidence": "Kering's expansion into new luxury segments", "position": 3, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "kpi_overview", "function": "analyze_data", "notes": "Waterfall chart illustrates revenue bridge between H1 22 and H1 23.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/18", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-18", "loopMatches": [ { "to": 24, "from": 17, "name": "Maturity Curve", "slug": "36-maturity-curve", "bestFor": "Digital transformation, capability building, benchmarking", "matchId": "f2340bcf-90ff-467f-bfcf-04f4f4e81e7e", "evidence": "Kering's progress in the luxury market", "position": 1, "objective": "Highlighting Kering's growth and maturity", "structure": "Current Maturity Level -> The Gap to Next Level -> Required Capabilities -> The Roadmap", "confidence": 0.7, "description": "Show where you are on a progression and what it takes to reach the next level" } ], "arcBeatMatches": [ { "to": 24, "from": 17, "beatId": "7cb44931-e742-4b4f-91aa-50eb6555992e", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "The Breakthrough", "beatSlug": "rags-to-riches-the-breakthrough", "evidence": "Kering's expansion into new luxury segments", "position": 3, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "kpi_overview", "function": "analyze_data", "notes": "Includes commentary on EBIT margin dilution and CAPEX phasing.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/19", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-19", "loopMatches": [ { "to": 24, "from": 17, "name": "Maturity Curve", "slug": "36-maturity-curve", "bestFor": "Digital transformation, capability building, benchmarking", "matchId": "f2340bcf-90ff-467f-bfcf-04f4f4e81e7e", "evidence": "Kering's progress in the luxury market", "position": 1, "objective": "Highlighting Kering's growth and maturity", "structure": "Current Maturity Level -> The Gap to Next Level -> Required Capabilities -> The Roadmap", "confidence": 0.7, "description": "Show where you are on a progression and what it takes to reach the next level" } ], "arcBeatMatches": [ { "to": 24, "from": 17, "beatId": "7cb44931-e742-4b4f-91aa-50eb6555992e", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "The Breakthrough", "beatSlug": "rags-to-riches-the-breakthrough", "evidence": "Kering's expansion into new luxury segments", "position": 3, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/20", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-20", "loopMatches": [ { "to": 24, "from": 17, "name": "Maturity Curve", "slug": "36-maturity-curve", "bestFor": "Digital transformation, capability building, benchmarking", "matchId": "f2340bcf-90ff-467f-bfcf-04f4f4e81e7e", "evidence": "Kering's progress in the luxury market", "position": 1, "objective": "Highlighting Kering's growth and maturity", "structure": "Current Maturity Level -> The Gap to Next Level -> Required Capabilities -> The Roadmap", "confidence": 0.7, "description": "Show where you are on a progression and what it takes to reach the next level" } ], "arcBeatMatches": [ { "to": 24, "from": 17, "beatId": "7cb44931-e742-4b4f-91aa-50eb6555992e", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "The Breakthrough", "beatSlug": "rags-to-riches-the-breakthrough", "evidence": "Kering's expansion into new luxury segments", "position": 3, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "kpi_overview", "function": "analyze_data", "notes": "Waterfall chart shows revenue bridge from H1 22 to H1 23.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/21", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-21", "loopMatches": [ { "to": 24, "from": 17, "name": "Maturity Curve", "slug": "36-maturity-curve", "bestFor": "Digital transformation, capability building, benchmarking", "matchId": "f2340bcf-90ff-467f-bfcf-04f4f4e81e7e", "evidence": "Kering's progress in the luxury market", "position": 1, "objective": "Highlighting Kering's growth and maturity", "structure": "Current Maturity Level -> The Gap to Next Level -> Required Capabilities -> The Roadmap", "confidence": 0.7, "description": "Show where you are on a progression and what it takes to reach the next level" } ], "arcBeatMatches": [ { "to": 24, "from": 17, "beatId": "7cb44931-e742-4b4f-91aa-50eb6555992e", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "The Breakthrough", "beatSlug": "rags-to-riches-the-breakthrough", "evidence": "Kering's expansion into new luxury segments", "position": 3, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "kpi_overview", "function": "analyze_data", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/22", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-22", "loopMatches": [ { "to": 24, "from": 17, "name": "Maturity Curve", "slug": "36-maturity-curve", "bestFor": "Digital transformation, capability building, benchmarking", "matchId": "f2340bcf-90ff-467f-bfcf-04f4f4e81e7e", "evidence": "Kering's progress in the luxury market", "position": 1, "objective": "Highlighting Kering's growth and maturity", "structure": "Current Maturity Level -> The Gap to Next Level -> Required Capabilities -> The Roadmap", "confidence": 0.7, "description": "Show where you are on a progression and what it takes to reach the next level" } ], "arcBeatMatches": [ { "to": 24, "from": 17, "beatId": "7cb44931-e742-4b4f-91aa-50eb6555992e", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "The Breakthrough", "beatSlug": "rags-to-riches-the-breakthrough", "evidence": "Kering's expansion into new luxury segments", "position": 3, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/23", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-23", "loopMatches": [ { "to": 24, "from": 17, "name": "Maturity Curve", "slug": "36-maturity-curve", "bestFor": "Digital transformation, capability building, benchmarking", "matchId": "f2340bcf-90ff-467f-bfcf-04f4f4e81e7e", "evidence": "Kering's progress in the luxury market", "position": 1, "objective": "Highlighting Kering's growth and maturity", "structure": "Current Maturity Level -> The Gap to Next Level -> Required Capabilities -> The Roadmap", "confidence": 0.7, "description": "Show where you are on a progression and what it takes to reach the next level" } ], "arcBeatMatches": [ { "to": 24, "from": 17, "beatId": "7cb44931-e742-4b4f-91aa-50eb6555992e", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "The Breakthrough", "beatSlug": "rags-to-riches-the-breakthrough", "evidence": "Kering's expansion into new luxury segments", "position": 3, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-d7b8-7009-a24d-c661ff2e1eed", "docSlug": "3dd79bb2096ceeaf1ac83b032d02fa77", "documentTitle": "Kering | Investor Presentation Deck | 55 slides", "authorId": "kering", "authorName": "Kering", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The chart uses a waterfall bridge to explain revenue variance between H1 2022 and H1 2023.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-d7b8-7009-a24d-c661ff2e1eed/24", "deckHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed", "deckAnchorHref": "/decks/019de075-d7b8-7009-a24d-c661ff2e1eed#slide-24", "loopMatches": [ { "to": 24, "from": 17, "name": "Maturity Curve", "slug": "36-maturity-curve", "bestFor": "Digital transformation, capability building, benchmarking", "matchId": "f2340bcf-90ff-467f-bfcf-04f4f4e81e7e", "evidence": "Kering's progress in the luxury market", "position": 1, "objective": "Highlighting Kering's growth and maturity", "structure": "Current Maturity Level -> The Gap to Next Level -> Required Capabilities -> The Roadmap", "confidence": 0.7, "description": "Show where you are on a progression and what it takes to reach the next level" } ], "arcBeatMatches": [ { "to": 24, "from": 17, "beatId": "7cb44931-e742-4b4f-91aa-50eb6555992e", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "The Breakthrough", "beatSlug": "rags-to-riches-the-breakthrough", "evidence": "Kering's expansion into new luxury segments", "position": 3, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }